Search results for Urelumab ELISA Kit
Urelumab ELISA Kit, ProteoGenix, KPTX241
Description of Urelumab ELISA Kit Introduction The Urelumab ELISA Kit is a highly sensitive and specific tool for the detection and quantification of Urelumab, a monoclonal antibody targeting the immune checkpoint receptor CD137. This kit is designed for use in various research applications, including drug development, biomarker discovery, and immunotherapy research. Structure of Urelumab Urelumab is a fully human IgG4 monoclonal antibody that binds to CD137, also known as 4-1BB. CD137 is a member of the tumor necrosis factor receptor superfamily and is expressed on activated T cells, natural killer cells, and dendritic cells. Urelumab has a molecular weight of approximately 148 kDa and consists of two heavy chains and two light chains. Activity of Urelumab Urelumab works by binding to CD137 and activating the immune system. CD137 is a co-stimulatory receptor that plays a critical role in regulating T cell activation and survival. Urelumab binding to CD137 leads to the activation of downstream signaling pathways, resulting in the proliferation and activation of T cells, as well as the production of pro-inflammatory cytokines and chemokines. This activation of the immune system can enhance the anti-tumor response and potentially lead to tumor regression. Application of Urelumab ELISA Kit The Urelumab ELISA Kit is a valuable tool for researchers studying the role of CD137 in immune regulation and cancer. This kit can be used to quantify the levels of Urelumab in various biological samples, such as serum, plasma, and cell culture supernatants. It can also be used to measure the levels of Urelumab in preclinical and clinical studies, providing valuable information on the pharmacokinetics and pharmacodynamics of this therapeutic antibody. Drug Development The Urelumab ELISA Kit is an essential tool for drug development, as it allows researchers to monitor the levels of Urelumab in preclinical and clinical studies. This information can be used to optimize dosing regimens and evaluate the efficacy of Urelumab in different patient populations. Additionally, the kit can be used to measure the levels of Urelumab in combination therapy studies, providing insights into potential drug interactions and synergistic effects. Biomarker Discovery The Urelumab ELISA Kit can also be used in biomarker discovery studies. By measuring the levels of Urelumab in patient samples, researchers can identify potential biomarkers that can predict response to Urelumab treatment. This information can be used to identify patients who are most likely to benefit from Urelumab therapy and to develop personalized treatment strategies. Immunotherapy Research Urelumab is a promising immunotherapy agent that has shown potential in various cancer types. The Urelumab ELISA Kit can be used in immunotherapy research to study the mechanisms of action of Urelumab and to evaluate its efficacy in different cancer models. It can also be used to monitor the levels of Urelumab in patients receiving immunotherapy, providing insights into treatment response and potential resistance mechanisms. Conclusion The Urelumab ELISA Kit is a valuable tool for researchers studying the role of CD137 in immune regulation and cancer. This highly sensitive and specific assay can be used to quantify the levels of Urelumab in various biological samples, providing valuable information for drug development, biomarker discovery, and immunotherapy research. With its ease of use and accurate results, the Urelumab ELISA Kit is an essential tool for advancing our understanding of Urelumab and its potential as a therapeutic antibody.
Host
Reactivity
Applications
Conjugation
Urelumab ELISA Kit, Abbexa, abx395130
Urelumab ELISA Kit is a quantitative ELISA kit for detection of Urelumab.Urelumab is a fully humanized agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. Urelumab specifically binds to and activates CD137-expressing immune cells, stimulating an immune response, in particular a cytotoxic T cell response, against tumor cells. Urelumab has been used in trials studying the treatment of Leukemia, Multiple Myeloma, Malignant Tumors, and Cancer-Solid Tumors and B-Cell Non-Hodgkin's Lymphoma. The antibody product was developed using Medarex's UltiMAb(R) technology and was the first UltiMAb-derived antibody in clinical development by Bristol-Myers Squibb under the December 2003 agreement with Medarex. In December 2008, enrolment was stopped for all urelumab studies following the occurrence of two hepatotoxicity-related deaths. Several years later, the clinical study on Urelumab was restarted. At present, the approval of the monoclonal antibody has not been disclosed in the relevant drug approval agency.
Host
Reactivity
Human
Applications
ELISA
Conjugation
Please provide the required information below so that we can quickly source your products.